Verzenio/Verzenios (abemaciclib) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Verzenio/Verzenios (abemaciclib) vs Enhertu (fam-trastuzumab deruxtecan-nxki)
Verzenio (abemaciclib) is a CDK4/6 inhibitor used primarily in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, often in combination with an aromatase inhibitor or fulvestrant. Enhertu (fam-trastuzumab deruxtecan-nxki), on the other hand, is an antibody-drug conjugate specifically targeting HER2-positive breast cancers and is used in patients who have previously received two or more anti-HER2-based regimens. The choice between Verzenio and Enhertu would depend on the hormone receptor and HER2 status of the breast cancer, with Verzenio being suitable for HR-positive, HER2-negative cases, and Enhertu being appropriate for HER2-positive cases, highlighting the importance of tumor biomarker testing in guiding treatment decisions.
Difference between Verzenio/Verzenios and Enhertu
Metric | Verzenio/Verzenios (abemaciclib) | Enhertu (fam-trastuzumab deruxtecan-nxki) |
---|---|---|
Generic name | Abemaciclib | Fam-trastuzumab deruxtecan-nxki |
Indications | HR-positive, HER2-negative advanced or metastatic breast cancer | HER2-positive breast cancer, gastric cancer |
Mechanism of action | CDK4 & CDK6 inhibitor | HER2-directed antibody and topoisomerase inhibitor conjugate |
Brand names | Verzenio, Verzenios | Enhertu |
Administrative route | Oral | Intravenous |
Side effects | Diarrhea, neutropenia, nausea, abdominal pain, infections | Nausea, neutropenia, vomiting, hair loss, constipation |
Contraindications | Hypersensitivity to abemaciclib or ingredients | Hypersensitivity to fam-trastuzumab deruxtecan-nxki or ingredients |
Drug class | Antineoplastic agent | Antibody-drug conjugate |
Manufacturer | Eli Lilly and Company | Daiichi Sankyo and AstraZeneca |
Efficacy
Verzenio (Abemaciclib) Efficacy in Breast Cancer
Verzenio, known generically as abemaciclib, is a targeted therapy approved for the treatment of certain types of breast cancer. Specifically, it is indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. As a CDK4/6 inhibitor, Verzenio works by interfering with the proliferation of cancer cells. Clinical trials have demonstrated its efficacy in both monotherapy and in combination with endocrine therapy. For example, in the MONARCH 2 study, Verzenio in combination with fulvestrant significantly improved progression-free survival compared to fulvestrant alone in women with HR+, HER2- advanced breast cancer who had progressed following endocrine therapy.
In the MONARCH 3 trial, abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy also showed a significant improvement in progression-free survival compared to the aromatase inhibitor alone in postmenopausal women with HR+, HER2- advanced breast cancer. Moreover, the MONALEESA trials, which investigated a similar class of drugs, further support the efficacy of CDK4/6 inhibitors in this patient population, suggesting that Verzenio may offer a valuable treatment option in the management of HR+, HER2- advanced or metastatic breast cancer.
Enhertu (Fam-Trastuzumab Deruxtecan-nxki) Efficacy in Breast Cancer
Enhertu, with the generic name fam-trastuzumab deruxtecan-nxki, is an antibody-drug conjugate approved for the treatment of adults with unresectable or metastatic HER2-positive breast cancer. It is indicated for patients who have received two or more prior anti-HER2-based regimens in the metastatic setting. Enhertu combines trastuzumab, a HER2-targeting antibody, with a cytotoxic drug, allowing for the direct delivery of the chemotherapy to the cancer cells. Clinical trials have shown significant efficacy for Enhertu in this patient population.
For instance, the pivotal DESTINY-Breast01 trial demonstrated that Enhertu provided a substantial improvement in response rate and progression-free survival in patients with HER2-positive metastatic breast cancer who had previously been treated with HER2-targeted therapies. The overall response rate was remarkably high, and the duration of response indicated a meaningful clinical benefit. These results have established Enhertu as a critical treatment option for patients with HER2-positive breast cancer who have progressed on prior therapies, offering hope for improved outcomes in a population with historically limited options.
Regulatory Agency Approvals
Verzenio/Verzenios
Enhertu
Access Verzenio/Verzenios or Enhertu today
If Verzenio/Verzenios or Enhertu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us